Labrys Biologics has made key executive appointments to lead the development of RN-307, a Phase II anti-CGRP monoclonal antibody for the treatment of chronic migraine. Marcelo Bigal, M.D., Ph.D., joins the company as chief medical officer, Michael Chang, Ph.D., as vice president of project management, Michele Bronson, Ph.D., as vice president of regulatory and quality, Rafael Escandón, Ph.D., MPH, as vice president of clinical operations, and Henry Stern as executive director of CMC.   “Th...